Comparison of single-dose oral granisetron versus intravenous ondansetron in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy: a multicenter, double-blind, randomized parallel study.

Perez, Edith A.; Hesketh, Paul J.; Sandbach, John F.; Reeves, John J.; Chawla, Suraj; Markman, Maurie; Hainsworth, John D.; Bushnell, William D.; Friedman, Carl J.

doi:10.1200/jco.1998.16.2.754

Cited by 120 publications

(72 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…But in case of delayed emesis the antiemetic protection had achieved 43.3% in children receiving ondansetron and on the contrary, 80% in children treated with granisetron who had achieved complete response and their observation was very much statistically significant 1 .Our observation had also matched with the study done by Friedman et al, where they had showed that at 48 hours of treatment, granisetron group of children had achieved A separate study was done by Perez et al, where they compared the single oral dose of granisetron versus IV ondansetron to prevent CRNV by moderate emetogenic chemotherapeutic agents and they observed no significant emetogenic control during 24 hours of chemotherapy 23 ,which are against our observations, where it was found that ondansetron group of children achieved 60% complete response at 48 hours, on the other hand, granisetron group had achieved 93.3% complete response following chemotherapy and the findings were statistically significant.…”

Section: Discussionsupporting

confidence: 70%

“…Confident interval (CI) was 95% and their subjective assessment had revealed no difference. The investigators had concluded that single 24 mg oral ondansetron is safe and effective compared to single IV infusion of 10ìgm/kg of granisetron in the prevention of nausea vomiting in high emetogenic chemotherapy 11 , which is in contrast to study done by Perez 23 . But our findings had proved that granisetron is more effective than ondansetron in the prevention of both acute (90% vs 70%) and delayed onset (80% vs 43.4%) nausea and emesis.…”

Section: Discussioncontrasting

confidence: 52%

See 1 more Smart Citation

Randomized Double Blind Trial to Compare the Efficacy of Granisetron And Ondansetron in Controlling Emesis in Children with Acute Lymphoblastic Leukemia

Siddique

Hafiz

Jamal

et al. 2013

Bangladesh J Child Health

View full text Add to dashboard Cite

Methods: In this randomized double blind trial 60 children (4-11 years) with acute lymphoblastic leukemia (ALL) who received high dose methotrexate (HDMTX-2.5gm/ m 2) . Each patients received either ondansetron 4 mg or granisetron 1mg (n=30) orally half an hour before HDMTX. Nausea and vomiting were assessed based on ''modified Morrow Assessment of Nausea and Emesis'' (MANE) scale for application to the children. Results: Complete response of granisetron significantly differed from ondansetron from day 2-4 (delayed emesis) (p=0.028).Complete response to acute CINV

show abstract

Section: Discussionsupporting

confidence: 70%

Section: Discussioncontrasting

confidence: 52%

Randomized Double Blind Trial to Compare the Efficacy of Granisetron And Ondansetron in Controlling Emesis in Children with Acute Lymphoblastic Leukemia

Siddique

Hafiz

Jamal

et al. 2013

Bangladesh J Child Health

View full text Add to dashboard Cite

show abstract

“…In directly comparative, single-agent studies of 5-HT 3 -receptor antagonists that permitted concomitant corticosteroid use [39,52], the addition of the steroid improved total control rates by 9.8%-13.4% at 24 hours and by 4.7%-8.7% at 48 hours postchemotherapy. Results from a study investigating optimum corticosteroid doses suggest that a dexamethasone dose of 20 mg be used as standard prophylaxis in combination with 5-HT 3 -receptor antagonists [72] ( Table 3).…”

Section: Potential For Corticosteroid Combinationmentioning

confidence: 99%

“…5-HT 3 -receptor antagonists have become the agents of choice in preventing acute CINV following both moderately and highly emetogenic chemotherapy [11,51]. Complete response and total control rates seen with specific drugs range from 60%-80% for moderately emetogenic chemotherapy [4,[52][53][54], 40%-60% for cisplatin-containing therapy [4,33,55,56], and 25%-60% for high-dose cisplatin regimens [33,35,47,57,58].…”

Section: Optimizing Efficacymentioning

confidence: 99%

Chemotherapy-Induced Nausea and Vomiting: The Importance of Acute Antiemetic Control

Schnell¹

2003

The Oncologist

189

167

View full text Add to dashboard Cite

Nausea and vomiting are two of the most feared side effects of cancer chemotherapy and radiotherapy. Chemotherapy-induced nausea and vomiting can be broadly categorized as acute (occurring within 24 hours of therapy), delayed (persisting for 6-7 days after therapy), or anticipatory (occurring prior to chemotherapy administration). Breakthrough and refractory nausea and vomiting describe the symptoms of uncontrolled emesis. Evidence suggests that good control of nausea and vomiting during the acute period correlates with the control of delayed emesis. Conversely, protection failure during the first 24 hours has a high predictive value for delayed emesis in the same cycle.The 5-HT 3 -receptor antagonists, regarded as the 'gold standard' in antiemetic therapy, are the first-line treatment for moderately and highly emetogenic chemotherapy and radiotherapy regimens in adults and children. Evidence suggests that the 5-HT 3 -receptor antagonists administered in combination with corticosteroids afford the best protection from symptoms of acute emesis and, by extrapolation, the most effective prevention of delayed emesis.Antiemetic therapeutic guidelines stress that the goal of therapy is to prevent cytostatic-induced nausea and vomiting. Therefore, the prophylactic use of the most effective antiemetic regimen-taking into consideration the emetogenicity of the chemotherapy and individual patient characteristics-must be adhered to in order to prevent acute, delayed, and anticipatory nausea and vomiting.

show abstract

“…When the trial was initiated granisetron was available in Denmark for intravenous use only. It has now been shown that a single oral dose of 2 mg granisetron is as effective as intravenous treatment with a serotonin antagonist (Perez et al, 1998).…”

Section: Discussionmentioning

confidence: 99%

Granisetron compared with prednisolone plus metopimazine as anti-emetic prophylaxis during multiple cycles of moderately emetogenic chemotherapy

Sigsgaard

Herrstedt

et al. 1999

Br J Cancer

View full text Add to dashboard Cite

Summary This randomized, double-blind, double-dummy parallel study compared the anti-emetic efficacy and tolerability of the serotonin antagonist granisetron with prednisolone plus the dopamine D 2 antagonist metopimazine during nine cycles of moderately emetogenic chemotherapy. Chemotherapy naive women with stage I or II breast cancer scheduled to intravenous cyclophosphamide, fluorouracil and methotrexate or cyclophosphamide, epirubicin and fluorouracil every 3 weeks were included. Patients received a single intravenous dose of granisetron 3 mg or a 3-day oral treatment with prednisolone 25 mg once a day plus metopimazine 30 mg four times a day. A total of 223 women were enrolled and 218 patients (97.8%) were evaluable for efficacy. Granisetron (n = 109) was superior to prednisolone plus metopimazine (n = 109) in the prophylaxis of acute nausea and vomiting during the first cycle of chemotherapy (P < 0.001) and prednisolone plus metopimazine was superior on days 2-5 (P = 0.002). Overall, granisetron was superior on days 1-5 (P = 0.009). The median number of cycles completed with granisetron was five (95% confidence interval 4-6) compared with two (95% confidence interval 2-2) for prednisolone plus metopimazine (P = 0.0019). Constipation and rash were reported more frequently with granisetron (P < 0.001 and P = 0.043 respectively) and palpitations more frequently with prednisolone plus metopimazine (P = 0.015). In conclusion, the number of cycles completed with granisetron was significantly higher than the number completed with prednisolone plus metopimazine, but the anti-emetic efficacy of both treatments declined during multiple cycles of moderately emetogenic chemotherapy.

show abstract

Comparison of single-dose oral granisetron versus intravenous ondansetron in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy: a multicenter, double-blind, randomized parallel study.

Cited by 120 publications

References 14 publications

Randomized Double Blind Trial to Compare the Efficacy of Granisetron And Ondansetron in Controlling Emesis in Children with Acute Lymphoblastic Leukemia

Randomized Double Blind Trial to Compare the Efficacy of Granisetron And Ondansetron in Controlling Emesis in Children with Acute Lymphoblastic Leukemia

Chemotherapy-Induced Nausea and Vomiting: The Importance of Acute Antiemetic Control

Granisetron compared with prednisolone plus metopimazine as anti-emetic prophylaxis during multiple cycles of moderately emetogenic chemotherapy

Contact Info

Product

Resources

About